Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 2
1999 1
2002 3
2003 2
2004 2
2005 4
2006 7
2007 6
2008 1
2009 2
2010 3
2011 5
2012 4
2013 3
2014 3
2015 10
2016 3
2017 9
2018 11
2019 8
2020 10
2021 11
2022 12
2023 15
2024 10
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Bornhäuser M, et al. Among authors: burchert a. JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605. JAMA Oncol. 2023. PMID: 36757706 Free PMC article. Clinical Trial.
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Burchert A, et al. J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16. J Clin Oncol. 2020. PMID: 32673171 Clinical Trial.
IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts.
Picard FSR, Lutz V, Brichkina A, Neuhaus F, Ruckenbrod T, Hupfer A, Raifer H, Klein M, Bopp T, Pfefferle PI, Savai R, Prinz I, Waisman A, Moos S, Chang HD, Heinrich S, Bartsch DK, Buchholz M, Singh S, Tu M, Klein L, Bauer C, Liefke R, Burchert A, Chung HR, Mayer P, Gress TM, Lauth M, Gaida M, Huber M. Picard FSR, et al. Among authors: burchert a. Gut. 2023 Aug;72(8):1510-1522. doi: 10.1136/gutjnl-2022-327855. Epub 2023 Feb 9. Gut. 2023. PMID: 36759154 Free PMC article.
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forstén S, Warfvinge R, Dufva O, Bouhlal J, Dhapola P, Duàn H, Laajala E, Kasanen T, Klievink J, Ilander M, Jaatinen T, Olsson-Strömberg U, Hjorth-Hansen H, Burchert A, Karlsson G, Kreutzman A, Lähdesmäki H, Mustjoki S. Huuhtanen J, et al. Among authors: burchert a. Leukemia. 2024 Jan;38(1):109-125. doi: 10.1038/s41375-023-02074-w. Epub 2023 Nov 2. Leukemia. 2024. PMID: 37919606 Free PMC article.
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Taube F, et al. Among authors: burchert a. Blood. 2022 Jan 6;139(1):87-103. doi: 10.1182/blood.2020009680. Blood. 2022. PMID: 34320176 Free article.
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study).
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kröger N, Ayuk FA, Stoelzel F, Middeke JM, Eder M, Bethge W, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante M, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau IW, Burchert A, Wulf G, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhaeuser M, Schmeller S, Schetelig J. Sockel K, et al. Among authors: burchert a. Blood. 2024 Oct 3;144(14):1532-1542. doi: 10.1182/blood.2024024342. Blood. 2024. PMID: 39007722
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Oelschlägel U, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhäuser M, Middeke JM, Thiede C. Eckardt JN, et al. Among authors: burchert a. Leukemia. 2023 Dec;37(12):2395-2403. doi: 10.1038/s41375-023-02061-1. Epub 2023 Oct 13. Leukemia. 2023. PMID: 37833543 Free PMC article.
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M. Röllig C, et al. Among authors: burchert a. J Clin Oncol. 2025 Jan;43(1):65-74. doi: 10.1200/JCO.24.00235. Epub 2024 Sep 16. J Clin Oncol. 2025. PMID: 39284116 Clinical Trial.
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
Kretschmer L, Ruhnke L, Schliemann C, Fransecky L, Steffen B, Kaufmann M, Burchert A, Schmid C, Hanoun M, Sauer T, Metzeler KH, Schäfer-Eckart K, Hänel M, Crysandt M, Jäger P, Krause SW, Dierks C, Klein S, Maguire N, Frenzel LP, Bücklein VL, Blau W, Kaiser U, Wegehenkel K, Höllein A, Seggewiss-Bernhardt R, Markgraf W, Fiebig F, Harig A, Schmidt-Brücken K, Thiede C, Middeke JM, Dillon R, Baldus CD, Serve H, Spiekermann K, Hiddemann W, Schlenk RF, Müller-Tidow C, Bornhäuser M, Röllig C. Kretschmer L, et al. Among authors: burchert a. Ann Hematol. 2025 Jul;104(7):3647-3654. doi: 10.1007/s00277-025-06496-7. Epub 2025 Jul 9. Ann Hematol. 2025. PMID: 40629154 Free PMC article.
136 results